PULMATRIX, INC. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
PULMATRIX, INC. (PULM) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $21.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2018-11-14
- PULMATRIX, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2016-06-30 was $52.00K.
- PULMATRIX, INC. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2016-03-31 was $83.00K.
- PULMATRIX, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2016 was $2.00K, a 94.59% decline from fiscal 2015.
- PULMATRIX, INC. noncash or part noncash acquisition, fixed assets acquired for fiscal 2015 was $37.00K.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2017-09-30 | $21.00K 10-Q · filed 2018-11-14 | |||
| 2016-12-31 | $2.00K 10-K · filed 2018-03-13 | |||
| 2016-06-30 | $52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $135.00K 10-Q · filed 2017-08-04 | ||
| 2016-03-31 | $83.00K 10-Q · filed 2017-05-05 | |||
| 2015-12-31 | $37.00K 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |